Infernal Ramblings
A Malaysian Perspective on Politics, Society and Economics

Misunderstanding the Free Market

Written by johnleemk on 10:21:45 am Sep 15, 2006.
Categories:

It is radical liberal orthodoxy that capitalism is bad, an unrestrained free market is evil, and the machinations of enterprise are undilutedly unfit for mankind. Often the targets of criticism for defending the free market are academics whose thought-out views don't comply with the politics of left-leaning radicals. Take, for instance, neo-Keynesian economist Paul Krugman. A renowned critic of George W. Bush and his administration, he was taking flak not too long ago for defending the existence of sweatshops in developing countries. (Never the mind the fact that he was right in that the market did produce the best possible solution to the problem of poverty - it created factories where people could eke out a better living than on the farm, even if by Western standards, wages were meagre.)

However, in failing to understand the economic theory behind free markets, anti-globalisation advocates and protectionist protestors have not grasped the fact that the market is still the best solution we have to the basic economic questions - who produces how much of what for who - despite its imperfections. At the same time, those conservatives whose habitual kneejerk reaction to any government role in the marketplace is to cite the free market are doing an injustice to the market by assuming it is perfect. It is not. There is a reason whole chapters in economics textbooks are devoted to the subject of market failure.

It is market failure that causes much of the privation and pollution we see in the world today. Liberals are absolutely right in blaming the market for the problems we see with our economies today. The problem is that instead of reforming and rehabilitating it, harnessing the price mechanism of free market economics to address the problems at hand, they seek to invent a whole new system altogether that obviates the need for the market to answer the basic economic questions. Whether by quotas, price controls, or what other barriers to trade you may have, they undermine the foundation of modern economics by focusing on its flaws instead of utilising its strengths to fill the flaws.

Now, even the reformed market is not going to be a perfect solution. But whoever expects a human system to perfectly address human problems is not living in a human world. The market, despite its imperfections, is the best thing we currently have, and until a new system - perhaps participatory economics or a gift economy - proves itself, we will have to settle for the market.

However, some of the market-based solutions offered here are not going to be palatable for die-hard conservatives, libertarians, minarchists or anarchists who decry any government intervention whatsoever in the market. The government does have a role to play in the economy - its job is to maximise social welfare. The only reason we have the market is that it has proven itself to be the best way we currently have to maximise - as economists put it - utility. Or, as one man of wit once said, the vice of capitalism is the unequal sharing of blessings, while the virtue of communism is the equal sharing of misery.

Let us first look at one key and absolutely undeniable failure of the market. Minarchists and anarchists can talk all they like about how ideally mankind will be able to work out our problems without government intervention here, but the fact is that the market simply canot act to provide public goods. I would say that the most key aspect of a public good is its non-excludability. You cannot exclude someone from enjoying the benefits of a public good. What this means is that you can take my property and my labour without providing me with anything in return.

An obvious example would be national defence. The free-rider problem exists here, because even if a mercenary army charged the populace it protects for its protection, without a government to levy taxes, it would be impossible to meet the fee demanded. Each fellow would reason that "Well, everyone else is going to pay for it, and I am not going to be harmed if I don't pay because they can't exclude me from the benefits of not having my house burned, my wife raped, and my children sold into slavery. So why don't I just...not pay?" The end result is that few, if any, would take the individual initiative to pay, and the mercenary army would either leave, or take it upon themselves to burn houses, rape wives, and sell children into slavery. Sure, perhaps the community might have learnt its lesson...but that's if there's a community left at all. And even then, people are notorious failures at remembering the lessons of history (case in point: the 2004 US presidential election).

We are thus left with a void the market cannot fill. No private initiative would be able to establish a standing army, a police force, or provide any other public good. This is the void governments fill for us. This is something indisputable, and I am not about to bother with the intellectually intriguing but pragmatically preposterous conjectures of minarchists and anarchists who would suggest otherwise.

A more controversial subject would be merit goods and demerit goods - goods that would benefit society if consumed at higher (or lower) levels than set by the market system. Obviously, what merit goods there are, if any, would be decided rather normatively (economic jargon for subjectively and questionably). Conservatives and liberals would have obvious disagreements about what constitutes a merit or demerit good, and some (probably libertarians) would argue that merit and demerit goods don't exist.

This is where the economic concept of externalities comes in. Externalities are where the market produces a situation that is less than desirable for society. However, this definition is a simplification of the economic theory behind externalities. Externalities are generally determined on an objective basis. The only thing subjective is the assumptions used to determine what constitutes an externality, and more importantly, the assumptions used to calculate the costs and benefits to society of a particular good or service.

Now, the fact that economists use assumptions to determine externalities is certainly something very debatable. However, it reflects the fact that we have imperfect information about our preferences and society's preferences. There's also the fact that it's extremely difficult to debate the existence of an externality.

Here, we have public goods to thank. Let's look at two examples of externalities: pollution and traffic congestion. Pollution exists because a clean environment is a public good. Nobody owns clean air or water. Nobody owns the sound of a bubbling brook or the sky on a sunny day. As a result, everyone is free to do what they like with these resources, regardless of the costs imposed on others. It is this that represents a key attribute of externalities - they either constitute a cost or benefit to someone not party in a transaction. Take a polluting factory near a river. It creates a cost for those who would like to use the river and the surrounding area, but this is a cost not reflected in its bottom line. This cost is not paid by the owners of the factory or their clients. It is a burden suffered by those who would like to enjoy a cleaner river and a greener view - it is an externalised cost.

The same applies to the problem of traffic congestion. It costs practically nothing to get on the road - perhaps on some highways there is a toll to pay, but otherwise, all you need is a hunk of steel on wheels with a combustion engine and a tank of petroleum, and you're set. The problem that arises is that same old free-rider problem. Everyone wants to attain the benefits of using the road. However, some people would gain more utility (benefit more) from the road than others. Someone in a hurry for a meeting to seal a deal would clearly pay those joyriding buggers clogging up the road to get off it. Because there is no market here, an externality arises - just as when there was no market for a clean environment.

The solution in both cases is to establish a market. What can be done in the case of pollution is to establish a market for pollution through the use of pollution permits. The key word here is a market. The government ought not to set a price on pollution, or absolutely mandate that people or enterprises do this or do that. The goal is to provide an incentive for them to do this or do that, and this is achieved by the market for pollution. What is done is that the government determines the maximum level of pollution they would like to see (something not too hard to do objectively), and then require that all polluters own a permit for every X quantity of pollution they emit. The government, being the sole distributor of permits, would then be able to limit pollution as much as desired within practical constraints. The operative bit here is that companies may buy or sell permits as they like. The price mechanism would then set the price of a pollution permit, and thereby internalise the costs of pollution by incorporating it into the costs of production. Those who find it cheaper not to pollute can then sell their permits on the market to those who can't afford not to pollute. The eventual result is that pollution goes down - this has been demonstrated both in the United States and the European Union, where such schemes were tremendously successful.

Although a similar system has not been implemented for traffic congestion yet, we are seeing the rise of traffic congestion fees in many cities around the world. In this case, the government requires all cars in a certain area of the city at a certain time of the day (e.g. office hours) to own a permit. Those who can't afford to pay the price of the permit (which is in this case government-set; trading is illegal) will simply have to get around by another form of transport or not enter this area of the city at all. (If you think this is unfair, it might be a good idea to review how the price mechanism and the concept of utility in economics work - simply put, if the cost to the traveller is too high to warrant entering the area by car, then the traveller does not benefit enough to warrant paying the price, and can maximise his individual benefit by spending the price of the permit on other goods.)

Even some aspects of the socialist platform, such as subsidised education, can be incorporated into capitalism by means of internalising externalities. Many economists have suggested that education is a positive externality, because it benefits the public at large. It is not just the student or the education institution who benefits if she gets a degree - it is her future spouse, her future employer, her future colleagues, and so forth. As a result, the argument goes, education ought to be considered a merit good and thus be at least partially government-funded. And of course, the market system has also been brought to bear on this problem through schemes such as school vouchers.

The last area of discussion for today is the touchy subject of monopolies. Conservatives justify the existence of monopolies as a natural end result of the free market, and that should the monopoly not act in accordance with the will of the consumer, other firms will spring up and gain market share. Liberals, on the other hand, are all too well aware of the dangers of monopolies, and generally have the right idea - some government regulation is inevitable in this area.

A monopoly harms the market and consumers in a number of ways. One is by raising barriers to entry - it blocks access to the market by other firms. One example of this was covered in the September 4th issue of Fortune which discussed how Intel used threats and predatory pricing to get consumers not to buy from rival chip-maker AMD. (Predatory pricing is when a firm intentionally underprices its goods - effectively accepting a loss on them - so as to gain an unfair edge over rival competitors, who may offer better quality, but lose out simply because the monopoly has vast resources to amass at its behest.) Other controversial tactics may include collusion, whereby many companies secretly carve up a market amongst themselves at an artificially high price instead of competing to drive prices down. Those old enough to remember the oil crises of the 1970s caused by OPEC should note that this was an example of collusion by OPEC's members to split the global oil market amongst themselves.

Of course, there are a number of objections to the economic theory about monopolies. Predatory pricing is untenable for long periods of time because a firm will eventually go out of business if it prices its goods below the costs of production. However, this argument fails to account for the huge cash reserves any longstanding monopoly would be wont to amass - Microsoft is drowning in money it doesn't know what to do with. A company does not have to run predatory price campaigns forever - just long enough to drive the nascent competition out of business, and to discourage potential competitors from joining the fray. Collusion is also a definitely untenable tactic, as demonstrated by game theory - thanks to the free-rider problem, each member will try to gain an edge by subtly under-pricing their products, and eventually the cartel will compete itself to death. The OPEC cartel eventually collapsed, after all.

Nevertheless, despite what many may say, monopolies do exist. Certainly, there are natural monopolies in some areas - perhaps not public utilities (although this would likely apply only to huge countries such as the United States), but in other areas - postal service, for instance. Government regulation and intervention is needed to some degree in order to maintain the basic requirements of a free market, such as low barriers to entry. Allowing monopolies to become a government unto themselves would be tantamount to government intervention in the market, except on the behalf of a company instead of the public.

Notably, I have not discussed the famous abuses of government officials of their authority to favour particular business interests in this article. The reason for this is that it is so absurdly clear that this runs contrary to the norms of a free market that there is no need to discuss such government intervention. Subsidies and other protectionist measures are rarely, if ever, justifiable. A government that supports the free market should not necessarily be a "pro-business" government.

The free market, as any economics text can tell you, is an imperfect beast. It can't help being that way - after all, humans run it. However, it is the best mechanism we have to run the economy. The key thing to keep our eyes on is the basic goal of any economic system - to maximise social welfare (or utility, in the parlance of economists). Properly regulated and adapted, the free market can work to address many of the problems facing the global economy today.


If you'd like to keep informed about updates to the site, consider subscribing to our web feed:

Infernal Ramblings is a Malaysian website focusing on current events and sociopolitical issues. Its articles run the gamut from economics to society to education.

Infernal Ramblings is run by John Lee. For more, see the About section. If you have any questions or comments, do drop him a line.


Comments

Thoughts? Comments? Discuss this and other ramblings at the forums.
(Alternatively, contact the author privately.)

Related comments from forum thread "Medicinal Monopolies":
johnleemk
Infernally Rambling Thoughtless Mind
Head Administrator
Posts: 948
IP Logged

Posted at 6:37:34 am Nov 2, 2005
One of the major problems I see facing modern medicine is the appropriate pricing of medicines. You see, it costs a lot to develop modern drugs - you not only have to pay for researching and marketing it, but also for test trials, etc. Furthermore, it also involves a lot of investment in time on the part of medical companies - a lot of time, on the scale of decades, even. If a drug doesn't pan out by say, not getting approval from the US Food and Drugs Administration, they may have wasted millions of dollars on nothing. As a result, medicinal companies need to charge higher and higher prices to recoup their costs.

However, to be able to charge such high prices, the demand for the drug must not be very elastic (the customers must not be turned off by a huge rise in the price of the drug). And in a market where other drug companies can be selling similar medicines, demand tends to be rather, well, elastic. This makes it financially unfeasible to develop drugs, especially complicated ones like those for AIDS or cancer. After all, what's the point when your competitor will be selling the same drug as yours under a different name within a few months? You might call this market failure, but the market has done nothing wrong; it's just impossible to profit from developing complex drugs.

Therefore, the governments of the world have stepped in to encourage drug development by awarding 20-year patents to drug discoverers. For 20 years, the company that discovered the drug will be the only one in control of who gets the drug - it's a monopoly. Now, this might be a good thing, except for the fact that once again, you've got the nasty market to contend with - the prices are high, remember? With diseases that affect mainly the poor, such as AIDS, this can cost millions of lives for the sake of a few dollars.

Sure, you could argue that the government could step in, but how? If it forces companies to lower their prices, there will no longer exist any incentive to develop new drugs. If the government itself subsidises drugs, there will be an incredible cost to taxpayers that many would find unconscionable. (Hey, remember the prices were artificially jacked up by the gifting of a monopoly to the drug manufacturers?) Arguably, socialism has come full circle - the interference in the market has come back to bite socialists in the ass. (Even though the measure is pro-business, remember it interferes with the workings of a free market.)

Some would argue that the monopoly is a natural monopoly, and that we should step aside and allow the free market to work. Such is the economic orthodoxy, but it's easy to say this to an audience of educated (and probably not dieing or starving) professionals. It's another thing to say this to the face of those who will face a struggle with cancer or AIDS for every day of the rest of their lives. A humane but practical solution has to be found.

Of course, there are also the even more extremist who would question that statement. After all, worshipping the omnipotent, omniscient free market is the "in" thing of economics nowadays. However, anyone who has ever bothered to read and comprehend an undergraduate economics textbook knows such a "free market is always right" stance to not only be wrong but downright dangerous. The free market is a means to an end, not an end in itself.

Economics teaches that the market exists only to produce and allocate goods and services. Once you have understood this, all the romance and mysticism of the free market are gone. But if you don't stop there and dig further into your undergraduate textbook, you'll find that the market isn't even always right when it comes to the distribution of goods and services - indeed, it can be horribly, horribly wrong. That's why the term "market failure" has been coined. The market fails when it allows a monopoly or oligopoly to erect barriers to entry, when it allows imperfect information, or when it allows externalisation of costs. The market is an imperfect tool - a good one, mind you, but nevertheless, rough around the edges.

Thus, we return to the original question - how do we provide drugs at an affordable cost without stifling the incentive to research and manufacture such drugs? We've struck subsidies and the outright removal of the patent system without replacing it off our list, so what's next? One common solution is to lower the length of the patents so that the drug recipe will be released into the hands of other companies sooner. This is just tinkering with the system, and offers no real solution. Furthermore, by lowering the length of the patent, the incentive to research costly drugs will also dissipate somewhat.

So we have to cross that one off our list. What's next? Well, here's a thought - an impractical one, but still a thought - drug bounties. Simply, governments would award the first one to come up with a drug that cures AIDS/cancer/whatever a certain amount of money, commensurate with the importance of the drug. This of course has its drawbacks - to be effective, the taxpayers will again have to open their wallets, and the price may be difficult to optimise (how do you know whether you're paying too much or too little for the cure for cancer?).

So, as you can probably tell by now, there is no real answer. There's no solution - at least, one isn't anywhere in sight in the near future. Still, it's quite the challenge, and you mark my words - the man who discovers how to optimise the production and distribution of drugs will win the Nobel Prize in economics. It's quite simple - in this case, there has been no market failure. So now we just have to figure out how to stimulate costly drug production without the help of the market. Well, it's not that simple. But you get my point.
Last five replies (3 comments not shown):
tanstaafl
Member
Posts: 9
IP Logged
Posted at 1:31:12 pm Mar 16, 2007
How exactly does having an FTA reduce or discourage corrupt practices? Anecdotal evidence would seem to suggest that it is neutral or in some cases increases corruption

http://www.counterpunch.com/vargas03122007.html

As John has stated previously in an earlier post, there is really no conclusion that can be drawn at this time on the FTA that is currently being negotiated at this time. However, I am still uncomfortable with how many free trade proponents glibly dismiss the potential downsides without really delivering a solution on how these problems are supposed to be dealt with.

As far as Malaysia is concerned, the last thing it needs right now social turmoil cause by economic disruptions given the "outstanding" calibre of our government and our politicians.
jasoneight
Member
Posts: 3
IP Logged
Posted at 12:24:03 pm Apr 10, 2007
The article in the Sun makes sweeping statements about the MUFTA without providing actual facts and figures. That is probably closer to "intellectual bankruptcy" than the FTA itself.

Malaysia is currently in negotiations with the United States for a Free Trade Agreement (MUFTA) which is expected to ease the way for attracting more foreign direct investment to Malaysia.

Amongst the issues being negotiated is the strengthening of intellectual property rights (IPR) in Malaysia. Even though Malaysia already has high standards of Intellectual Property Rights (IPR) in the form of patents, trademarks and copyright, there is still a need to enhance the IP environment in order to recognize and reward research.

In order to attract foreign investment in the R&D sector, it is important to understand that foreign corporations invest not to make simple products but to produce those with high elements of innovation, creativity and design. This will help to promote foreign direct investment as it makes Malaysia more attractive for foreign investors that have invested heavily in research. This is especially so in the pharmaceutical industry which has been identified as a key growth sector under the Third Industrial Master Plan (IMP3).

US pharmaceutical companies spent US$55.2 billion on R&D in 2006 and there is a great possibility of a fraction of that amount that can be diverted to Malaysia with the FTA. (PhRMA news Feb 12, 2007)

However, there are some unwarranted fears in the industry about the MUFTA provisions on IPR that will cause difficulties to local drug manufacturers who are mainly producing generic drugs. Such fears and apprehensions are largely misconceived because stronger intellectual property (IP) protection does not hurt local generic drug manufacturers or make them lose out. Instead the opportunities for them become better as it will attract investments from large pharmaceutical companies with resulting spin-offs to the local generic drugs manufacturers in terms of joint ventures, contract manufacturing and R&D.

Even China, a nation hardly well-known for its IP laws, has actually passed regulations as early as 2002 to provide for 6 years of data exclusivity as from the date of marketing approval. In the “Regulations for Implementation of the Drug Administration Law,” effective September 2002, the definition of a new drug was modified in accordance with the Trade-Related Aspects of Intellectual Property Rights (TRIPS). The new Patent Law further harmonized China’s patent system with the rest of WTO member countries. In fact, China’s IP protection for pharmaceuticals has gradually been coming into conformity with international standards over the past several years.

The result of China’s IPR strategy is clear with the who’s who of global pharmaceutical companies moving into China in a big way. Today, multinationals have over 600 joint ventures with local companies in China.

AstraZeneca invested US$134 million in a manufacturing plant in Wuxi and is set to invest another US$100 million to open the AstraZeneca Innovation Centre China in 2009. It has a marketing arm that employs 2,500 people and has also created a division to support local clinical trials.

Novartis is collaborating with the Shanghai Institute of Material Medical Research, a leading Chinese R&D institute and it is constructing a US$83 million site for drug production and development in Changshu.

World leading pharmaceutical company Eli Lilly set up a research laboratory in cooperation with its Chinese partner Shanghai ChemExplorer in the Zhangjiang New and Hi-TechTechnological Park in Shanghai’s Pudong New District. World first-class research equipment has been installed in the lab and it has 230 scientists working in China. The China-based R&D team is the US-based firm’s largest R&D group overseas. Eli Lilly has also agreed to transfer its antibiotics manufacturing technology to leading Chinese company Hisun Pharmaceutical Co Ltd. The move is part of Eli Lilly’s US$70 million global initiative to address multi-drug resistant tuberculosis, in partnership with the World Health Organization. It also has a factory in adjacent Suzhou city, east China’s Jiangsu province.

Meanwhile, Pfizer, has invested over US$500 million in China and will also set up a new R&D center in Shanghai with initial spending of US$25 million over the next few years.

In 2002, GlaxoSmithKline (China) Investment Co. Ltd. (GSK) was officially established and became one of the largest multinational pharmaceutical companies in China. GSK has established five legal entities encompassing four manufacturing facilities (three are joint ventures) with a total registered capital of over US$230 million in China. It has offices in 29 major cities (including Hong Kong) with 2,800 employees nationwide. The various companies continue to create jobs and provide training for business managers and professional staff in the pharmaceutical industry, as well as provide business opportunities to local partners and medical professionals.

GSK signed an agreement with China’s Simcere Pharmaceutical Group to manufacture and sell a cheaper version of its bird flu drug Relenza for use in poorer countries. The terms of the licensing deal allows Simcere to manufacture and sell zanamivir, the active ingredient in Relenza, in China, Indonesia, Thailand, Vietnam and other less developed countries.

Relenza, together with Roche’s antiviral Tamiflu, are the only drugs considered effective against the human form of H5N1 influenza, and would be the first line of defense in the event of a worldwide H5N1 influenza pandemic.

Roche has two manufacturing plants in China, one of which is a high tech manufacturing facility in Shanghai producing the cancer medicine Xeloda and the transplantation medicine CellCept. Both Xeloda and CellCept are major medicines in the Roche portfolio. Xeloda is a tumour-activated oral chemotherapeutic agent used to treat breast and colorectal cancer. CellCept, used as a foundation for immuosuppression, helps transplant patients to live a longer and healthier life.

Roche also opened its new R&D center in Shanghai which its fifth Pharma research site globally. The center will work with JiangJiang High Tech Park to promote the district to become a leading biomedical research based epicenter of drug research and discovery in China. In addition, it is working in collaboration with the two Chinese National Human Genome Centers to conduct genetic epidemiology studies to identify genetic predispositions to diseases such as diabetes or Alzheimer’s.

Further more, like GSK, Roche is the maker of Tamiflu, an important bird flu vaccine and the company granted a first sub-license to Shanghai Pharmaceutical Group for the production of Tamiflu for pandemic use in China.

If China can see tremendous benefit of stronger IP protection, certainly Malaysia should be able to recognize the advantages of it as well and not miss the golden opportunity that the MUFTA presents in attracting new FDI and helping us move up the value chain in innovation and R&D.

Fears and apprehensions by our local generic drug makers are largely misconceived as the Government of Malaysia’s outlook on the pharmaceutical industry in general and the generics in particular is very bright. Instead of adopting a negative stance, one should first study the Third Industrial Master Plan 2006-2020 (IMP3) especially at pages 405-420 which clearly identified the pharmaceutical industry as one of the 20 target growth areas. The opportunities are tremendous for local generic drug manufacturers and their growth prospects are very positive.

There were 235 pharmaceutical companies registered with the Drug Control Authority, Ministry of Health in 2005, 148 producing traditional medicines and 87 manufacturing modern medicines. The majority of the companies in the industry comprise small and medium enterprises (SMEs), mostly producing generic drugs.

During the IMP2 period from 1996-2005, domestic investments in the pharmaceutical industry amounted to RM756.5 million or 75% of the total investment while foreign investments were valued at RM250.4 million. For this period, the domestic pharmaceutical market registered an average annual growth of 11 per cent. The sales of locally produced pharmaceutical products grew at an average annual rate of 10.8 per cent, from RM334 million in 1996 to RM852 million in 2005. Exports of pharmaceutical products grew at an average annual rate of 10.6 per cent, from RM194 million to RM494.3 million in 2005. This was a result of a significant expansion of production into a wider range of generic drugs with the expiry of more patented, branded pharmaceutical drugs. Generic versions of newly “off patented” products which are being developed and produced, include clavulanate, amoxicillin, omeprazole, ranitidine, loratadine, dexclorpheniramine, simvastatin and acyclovir.

In a DataMonitor report cited by the IMP3, with an annual anticipated growth rate of 7.5 per cent for the period 2005-2010, the global pharmaceutical market is projected to increase from USD534.8 billion in 2005 to USD762.2 billion by the end of 2010.

Patents of many drugs made by the US and European companies have either expired or will be expiring during the next few years. It is estimated that the patent expiry will involve about USD100 billion worth of branded drugs of major pharmaceutical companies. According to drug market research firm IMS Health, some USD16 billion worth of annual drug sales are expected to go off-patent in 2007 whereas in 2006, there was USD23 billion worth of patent expirations. Drugs with sales of USD160 billion are expected to come off patent by 2015, according to Datamonitor PLC (London, UK).

Joanna Chertkow, a pharmaceutical lead analyst at Datamonitor said, “It is expected that the raft of blockbuster patent expiries that will occur over the next ten years will lead to a rise in the volume of the generics market.”
This will create tremendous market opportunities for generics worldwide, which are expected to grow at an average annual rate of 10 per cent till 2011. For 2007, generics are expected to grow at the rate of 13 -14 per cent.

Moreover, there is also the relatively unexplored market for bio-generics which is estimated to grow at an annual average rate of 70 per cent during the period 2007-2011 and will generate a total revenue of more than USD16 billion by 2011.

For the IMP3 period, 2006-2020, investments in the pharmaceutical industry have been targeted at RM6.7 billion and exports are targeted to grow at an annual rate of 6.3 per cent to reach RM1.2 billion by 2020.

Indeed, our local generic drug manufacturers should seek to be globally competitive as in the theme in the IMP3 and fully exploit the opportunities available instead of lamenting on the negatives. The several strategic thrusts as set out in the IMP3 must necessarily be studied as to how to gain a greater share of the global pharmaceutical market, which, inter alia, include the encouraging of further efforts on R&D and commercialization, enhancing the development of expertise in drug research and the strengthening of the institutional support in the development and promotion of the industry.




jasoneight
Member
Posts: 3
IP Logged
Posted at 12:43:23 pm Apr 10, 2007
The article in the Sun mentioned that farmers in Malaysia will suffer if the MUFTA is signed but there are no details provided.

I remember some NGOs and other individual parties claimed in the press that our local farmers would be affected by the FTA, in that there will be an influx of rice from the US in the local market after the FTA and consequently affect local farmers.

But in fact, this is not the case.

In reality, rice production in Malaysia is not enough and we have to import 30 percent of our rice. This comes mainly from Vietnam which accounts for 420,000 tonnes or RM415 million worth of our rice import and from Thailand which accounts for some 300,00 tonnes of rice imports. This compares with only an import of 385 tonnes of rice from the US worth RM1.36 million.

If at all, then Malaysian rice is in fact competing with the rice from Vietnam and Thailand as the grade is the same, and not with that from the US, which is of a different grade and caters mainly to the Japanese and Koreans in the country.

Malaysian local white rice costs about RM2.20 per kilo while the rice from the US costs about RM10.25 per kilo. It is therefore clear that the rice from the US cannot compete with the local rice based on simple pricing and economics.


johnleemk
Infernally Rambling Thoughtless Mind
Head Administrator
Posts: 948
IP Logged
Posted at 1:23:48 pm Apr 10, 2007
Hm...nice research there, but your comments suspiciously resemble those of some government officials who have commented about the FTA, right down to the wording. :p
jasoneight
Member
Posts: 3
IP Logged
Posted at 1:34:34 pm Apr 11, 2007
The facts speak for themselves - plain and simple - not like those who mouth other sweeping, general and emotional statements.

These facts don't get reported in full often enough as they are not sensational and do not help sell papers.It is more dramatic to say that FTA destroy lives and take away our sovereignty.

Too often we forget how the Hong Kong economy was built.


Latest:
A New Malaysian Government May Be On Its Way
Popular:
A New Malaysian Government May Be On Its Way

Most Recently Read

  1. Analysing the Beatles' Success
  2. Ethnic Descent, Nationality and Race: What is a Malaysian?
  3. Malaysia's Poor Leaders, Each PM Worse than the Last
  4. A New Malaysian Government May Be On Its Way
  5. Economic Class and Education in Malaysia
  6. Productive, Allocative and Dynamic Efficiency: Trade-offs
  7. Abusing the Internet
  8. Malaysians Deserve Better Than Troops in the Streets
  9. Taiwan Earthquake Knocks Out Internet in Malaysia
  10. Absolute vs Comparative Advantage
Google
Latest active forum topics
Quoth the webserver...
One never goes so far as when one doesn't know where one is going.
— Goethe
Poll
Sorry, only registered users may vote. Please register or login.

There are currently no polls running.